Liver function and psoriasis drug: a safety check
NCT ID NCT06376474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the body processes Hemay005 tablets in people with mild or moderate liver problems compared to those with normal liver function. The goal is to find the right dose for patients with liver issues. 24 adults with psoriasis will take a single dose and have their blood levels measured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill quiet the immune attack behind psoriasis?
- Laser boost for stubborn psoriasis on hands and feet
- New oral pill HPP737 takes on psoriasis in Head-to-Head trial
- New oral pill HPP737 aims to clear psoriasis in phase 3 trial
- Psoriasis Patients' quality of life under the microscope
- Skin disease evolution under the microscope: a 17-Year look at what drives severity